Core Viewpoint - DLocal (DLO) has received a Zacks Rank 2 (Buy) upgrade, indicating a positive earnings outlook that may lead to increased stock price [1][3]. Earnings Estimates and Revisions - The Zacks Consensus Estimate for DLocal's earnings per share (EPS) for the fiscal year ending December 2025 is projected at $0.62, reflecting a 21.6% increase from the previous year [8]. - Over the past three months, the consensus estimate for DLocal has risen by 9.9%, indicating a trend of increasing earnings estimates [8]. Zacks Rating System - The Zacks rating system classifies stocks based on earnings estimate revisions, with DLocal's upgrade positioning it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns [10]. - The Zacks Rank system has a strong historical performance, with Zacks Rank 1 stocks averaging an annual return of +25% since 1988 [7]. Impact of Institutional Investors - Changes in earnings estimates significantly influence institutional investors' valuation models, leading to buying or selling actions that affect stock prices [4]. - The correlation between earnings estimate revisions and stock price movements underscores the importance of tracking these revisions for investment decisions [6].

Core Viewpoint - Apogee Therapeutics Inc. (APGE) has seen a 9.9% increase in share price over the past four weeks, closing at $40.98, with analysts projecting a potential upside of 129.1% based on a mean price target of $93.88 [1][12]. Price Targets - The average price target consists of eight estimates ranging from a low of $78 to a high of $116, with a standard deviation of $11.05, indicating a potential increase of 90.3% to 183.1% from the current price [2][9]. - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement direction [9]. Earnings Estimates - Analysts are optimistic about APGE's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has shown a strong correlation with near-term stock price movements [11][12]. - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 9.2%, with three estimates moving higher and no negative revisions [12]. Analyst Consensus - APGE holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential upside in the near term [13].

Core Viewpoint - Concentra Group (CON) has seen a 2.9% increase in share price over the past four weeks, closing at $22.03, with a mean price target of $28 indicating a potential upside of 27.1% [1] Price Targets and Analyst Consensus - The average price target consists of eight estimates ranging from a low of $25 to a high of $30, with a standard deviation of $1.85, suggesting a potential increase of 13.5% to 36.2% from the current price [2] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates and Market Sentiment - Analysts are optimistic about CON's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which historically correlates with stock price movements [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 1.5%, with three estimates moving higher and no negative revisions [12] Zacks Rank and Investment Potential - CON holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential for upside in the near term [13]

Group 1 - Birkenstock (BIRK) shares have increased by 4.1% over the past four weeks, closing at $54.76, with a mean price target of $68.88 indicating a potential upside of 25.8% [1] - The average of 17 short-term price targets ranges from a low of $57 to a high of $81, with a standard deviation of $7.34, suggesting a relatively high agreement among analysts [2] - Analysts are optimistic about BIRK's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which historically correlates with stock price movements [4][11] Group 2 - Over the last 30 days, the Zacks Consensus Estimate for BIRK's current year earnings has increased by 4%, with eight estimates moving higher and one lower [12] - BIRK holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13]

Core Viewpoint - Monte Rosa Therapeutics (GLUE) has seen a 22.5% increase in share price over the past four weeks, closing at $5.01, with a potential upside indicated by Wall Street analysts' mean price target of $16.14, suggesting a 222.2% increase from the current price [1] Price Targets and Analyst Estimates - The mean estimate consists of seven short-term price targets with a standard deviation of $3.98, where the lowest estimate of $10 indicates a 99.6% increase, and the highest estimate suggests a 299.2% surge to $20 [2] - A low standard deviation among price targets indicates a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Optimism - Analysts are optimistic about GLUE's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has shown a strong correlation with near-term stock price movements [11] - Over the last 30 days, three earnings estimates for the current year have been revised higher, leading to a 56.6% increase in the Zacks Consensus Estimate [12] Zacks Rank and Investment Potential - GLUE holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential upside in the near term [13]

Group 1 - Phathom Pharmaceuticals, Inc. (PHAT) shares have increased by 184.1% in the past four weeks, closing at $8.92, with a mean price target of $18.50 indicating a potential upside of 107.4% [1] - The mean estimate consists of eight short-term price targets with a standard deviation of $8.09, where the lowest estimate is $5 (44% decline) and the highest is $28 (213.9% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements [11][12] Group 2 - The Zacks Consensus Estimate for the current year has risen by 16% over the last 30 days, with one estimate increasing and no negative revisions [12] - PHAT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of potential gains, it suggests a positive direction for price movement [13]

Group 1 - The RealReal (REAL) stock closed at $5.71, showing a 13.1% gain over the past four weeks, with a mean price target of $10.10 indicating a potential upside of 76.9% [1] - The mean estimate consists of five short-term price targets with a standard deviation of $3.09, where the lowest estimate is $7 (22.6% increase) and the highest is $15 (162.7% increase) [2] - Analysts show strong agreement on the company's ability to report better earnings, which supports the view of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 64.3% over the past month, with no negative revisions [12] - REAL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting stock gains, they can indicate the direction of price movement [13]

Group 1 - ZipRecruiter, Inc. (ZIP) shares have increased by 43.4% over the past four weeks, closing at $6.25, with a mean price target of $8 indicating a potential upside of 28% [1] - The mean estimate consists of five short-term price targets with a standard deviation of $1.87, where the lowest estimate is $6 (4% decline) and the highest is $10 (60% increase) [2] - Analysts show a strong agreement in revising earnings estimates higher, which correlates with potential stock price movements [11] Group 2 - The Zacks Consensus Estimate for the current year has risen by 1.1% over the past month, with two estimates increasing and one decreasing [12] - ZIP holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of potential gains, it suggests a positive direction for price movement [13]

Core Viewpoint - Sagimet Biosciences Inc. (SGMT) shares have increased by 70.6% in the past four weeks, closing at $5.56, with a mean price target of $29.86 indicating a potential upside of 437.1% according to Wall Street analysts [1] Group 1: Price Targets and Analyst Estimates - The mean estimate consists of seven short-term price targets with a standard deviation of $20.44, indicating variability among analysts; the lowest estimate suggests a 10.1% decline, while the highest predicts a surge of 1105% to $67 [2] - Analysts' consensus on price targets is often questioned, as they may not accurately reflect the stock's future price movements [3][7] - A low standard deviation in price targets suggests a high degree of agreement among analysts regarding the stock's price direction, which can serve as a starting point for further research [9] Group 2: Earnings Estimates and Market Sentiment - Analysts are optimistic about SGMT's earnings prospects, as indicated by a strong agreement in revising EPS estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has risen by 26.4% over the past month, with four estimates increasing and no negative revisions [12] - SGMT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential upside [13]

Group 1 - HubSpot (HUBS) closed at $609.40, with a 1.1% gain over the past four weeks, and a mean price target of $763.91 indicating a 25.4% upside potential [1] - The mean estimate consists of 32 short-term price targets with a standard deviation of $66.58, where the lowest estimate is $645 (5.8% increase) and the highest is $930 (52.6% increase) [2] - Analysts show strong agreement on HUBS's ability to report better earnings, with a positive trend in earnings estimate revisions indicating potential upside [4][11] Group 2 - The Zacks Consensus Estimate for HUBS has increased by 49.9% over the past month, with 13 estimates going higher and no negative revisions [12] - HUBS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator, the direction of price movement it implies appears to be a good guide for potential gains [13]